Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs.

[1]  H. Nagasawa,et al.  Design of hypoxia-targeting drugs as new cancer chemotherapeutics. , 2006, Biological & pharmaceutical bulletin.

[2]  M. Stratford,et al.  Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4 , 2006, Molecular Cancer Therapeutics.

[3]  L. Hogarth,et al.  The thiopurines: An update , 2005, Investigational New Drugs.

[4]  W. Denny,et al.  Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. , 2005, Bioorganic & medicinal chemistry.

[5]  I. Stratford,et al.  Quinone bioreductive prodrugs as delivery agents. , 2004, Current drug delivery.

[6]  G. Elgemeie.  Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites. , 2003, Current pharmaceutical design.

[7]  W. Denny,et al.  Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. , 2003, Journal of medicinal chemistry.

[8]  P. Wardman.  Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. , 2001, Current medicinal chemistry.

[9]  M. Naylor,et al.  Recent advances in bioreductive drug targeting. , 2001, Mini reviews in medicinal chemistry.

[10]  D. Scudiero,et al.  P450 enzyme expression patterns in the NCI human tumor cell line panel. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[11]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[12]  D. Naughton,et al.  2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone. , 1999, Bioorganic & medicinal chemistry letters.

[13]  M. Grever,et al.  Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. , 1996, Journal of the National Cancer Institute.

[14]  R. Mulcahy,et al.  Nitrobenzyl phosphorodiamidates as potential hypoxia-selective alkylating agents. , 1994, Journal of medicinal chemistry.

[15]  D. Kirkpatrick,et al.  Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate. , 1986, Journal of medicinal chemistry.

[16]  S. Paine,et al.  The kinetics and mechanism of the reaction of p-nitrocumyl bromide with azide ions in dimethyl sulfoxide. Evidence for a heterolytic reaction , 1996 .